Skip to content

Registration now open for Stanford’s Big Data in Precision Health conference

The seventh annual Big Data in Precision Health conference will be held May 22 and 23 on the Stanford campus; registration is now open.

In just two months, Stanford will welcome academics, industry professionals and big data enthusiasts to its seventh annual Big Data in Precision Health conference.

The conference will be held May 22-23 at the Stanford University School of Medicine. It will showcase advances in precision health -- a personalized approach that stresses predicting, preventing and treating disease by utilizing technology and data science, as well as relationships with caregivers. The conference will feature new findings at the intersection of immense datasets and human health.

Registration is now open.

Dean Lloyd Minor, MD, will kick off the conference with introductory remarks, after which experts in engineering, patient care and data science will discuss and explore the current trends and technologies in big data. Highlighted topics include the evolving role of artificial intelligence in patient care, and how big data can inform better drug development.

Speakers include Kirsten Bibbins-Domingo, MD, PhD, professor and chair of the department of epidemiology and biostatistics at the University of California, San Francisco; Sanjay Basu, MD, a Stanford assistant professor of medicine; and Jeff Dean, PhD, senior vice president of Google AI. The full list of speakers can be found here.

The conference will also host a poster session for registrants to present their own work, as well as a corporate technical showcase, where members from industry can demonstrate their company's approach to big data.

Photo by Rod Searcey

Popular posts

Category:
Alzheimer's
One step back: Why the new Alzheimer’s plaque-attack drugs don’t work

A few closely related drugs, all squarely aimed at treating Alzheimer’s disease, have served up what can be charitably described as a lackadaisical performance. Stanford Medicine neurologist Mike Greicius explains why these drugs, so promising in theory, don’t appear to be helping patients much if at all.